Performance evaluation of a CRISPR Cas9-based selective exponential amplification assay for the detection of KRAS mutations in plasma of patients with advanced …
Y Shen, X Zhang, L Zhang, Z Zhang, B Lyu… - Journal of Clinical …, 2023 - jcp.bmj.com
Aims Pancreatic ductal adenocarcinoma (PDAC) is highly malignant, with shockingly
mortality rates. KRAS oncoprotein is the main molecular target for PDAC. Liquid biopsies …
mortality rates. KRAS oncoprotein is the main molecular target for PDAC. Liquid biopsies …
KRAS mutations in ctDNA: a promising new biomarker in advanced pancreatic cancer
C Montagut, J Vidal, L Visa - Annals of Oncology, 2018 - annalsofoncology.org
Pancreatic cancer (PC) is predicted to be the second leading cause of cancer-related
mortality in the next decade in Western countries [1]. Despite recent improvement with the …
mortality in the next decade in Western countries [1]. Despite recent improvement with the …
Efficient and accurate KRAS genotyping using digital PCR combined with melting curve analysis for ctDNA from pancreatic cancer patients
J Tanaka, T Nakagawa, K Harada, C Morizane… - Scientific Reports, 2023 - nature.com
A highly sensitive and highly multiplexed quantification technique for nucleic acids is
necessary to predict and evaluate cancer treatment by liquid biopsy. Digital PCR (dPCR) is …
necessary to predict and evaluate cancer treatment by liquid biopsy. Digital PCR (dPCR) is …
Prognostic Implications of Multiplex Detection of KRAS Mutations in Cell-Free DNA from Patients with Pancreatic Ductal Adenocarcinoma
MK Kim, SM Woo, B Park, KA Yoon, YH Kim… - Clinical …, 2018 - academic.oup.com
Abstract BACKGROUND Cell-free DNA (cfDNA) is known to provide potential biomarkers for
predicting clinical outcome, but its value in pancreatic ductal adenocarcinoma (PDAC) has …
predicting clinical outcome, but its value in pancreatic ductal adenocarcinoma (PDAC) has …
Mutant KRAS Circulating Tumor DNA Is an Accurate Tool for Pancreatic Cancer Monitoring
R Perets, O Greenberg, T Shentzer, V Semenisty… - The …, 2018 - academic.oup.com
Background Many new pancreatic cancer treatment combinations have been discovered in
recent years, yet the prognosis of pancreatic ductal adenocarcinoma (PDAC) remains grim …
recent years, yet the prognosis of pancreatic ductal adenocarcinoma (PDAC) remains grim …
Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer
F Watanabe, K Suzuki, S Tamaki, I Abe, Y Endo… - PLoS …, 2019 - journals.plos.org
Background Liquid biopsies enable the detection of circulating tumor DNA (ctDNA).
However, the clinical significance of KRAS-mutated ctDNA for pancreatic cancer has been …
However, the clinical significance of KRAS-mutated ctDNA for pancreatic cancer has been …
[HTML][HTML] Evaluation of circulating cell-free KRAS mutational status as a molecular monitoring tool in patients with pancreatic cancer
K Schlick, S Markus, F Huemer, L Ratzinger… - Pancreatology, 2021 - Elsevier
Background Pancreatic carcinoma carries a devastating prognosis and is the 4th leading
cause for cancer related death in the US and most European countries. Apart from imaging …
cause for cancer related death in the US and most European countries. Apart from imaging …
KRAS Mutant Allele Fraction in Circulating Cell-Free DNA Correlates With Clinical Stage in Pancreatic Cancer Patients
ZY Wang, XQ Ding, H Zhu, RX Wang, XR Pan… - Frontiers in …, 2019 - frontiersin.org
Background: The research on circulating tumor DNA (ctDNA) in pancreatic cancer (PC) has
emerged recently. Although the detection rate of the KRAS mutation in ctDNA was relatively …
emerged recently. Although the detection rate of the KRAS mutation in ctDNA was relatively …
[HTML][HTML] Ultrasensitive plasma ctDNA KRAS assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic ductal …
I Chen, VM Raymond, JA Geis, EA Collisson… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Precision oncology requires sensitive and specific clinical biomarkers. Carbohydrate
Antigen 19-9 (CA19-9) is widely used in pancreatic ductal adenocarcinoma (PDA) but lacks …
Antigen 19-9 (CA19-9) is widely used in pancreatic ductal adenocarcinoma (PDA) but lacks …
Multiplex Enrichment and Detection of Rare KRAS Mutations in Liquid Biopsy Samples using Digital Droplet Pre-Amplification
Oncology research is increasingly incorporating molecular detection of circulating tumor
DNA (ctDNA) as a tool for cancer surveillance and early detection. However, noninvasive …
DNA (ctDNA) as a tool for cancer surveillance and early detection. However, noninvasive …
相关搜索
- amplification assay kras mutations
- plasma of patients kras mutations
- plasma of patients amplification assay
- crispr cas9 kras mutations
- crispr cas9 amplification assay
- plasma of patients crispr cas9
- performance evaluation amplification assay
- plasma of patients performance evaluation
- performance evaluation kras mutations
- performance evaluation crispr cas9
- multiplex detection kras mutations
- kras genotyping cancer patients
- cancer monitoring mutant kras
- longitudinal monitoring pancreatic cancer
- clinical stage cancer patients
- prognostic implications kras mutations